Xencor Picks Top Dose For Kidney Cancer Drug After 45.5% Response Rate In Small Cohort

The company plans FDA talks on an accelerated approval path and a head-to-head trial against tivozanib, with cash it expects to last into 2029.

Share
Xencor Picks Top Dose For Kidney Cancer Drug After 45.5% Response Rate In Small Cohort

Xencor, a clinical-stage biotech that engineers antibody drugs for cancer and autoimmune disease, chose 400 mcg/kg as the proposed Phase 3 dose of its kidney cancer drug XmAb819 after 45.5% of 11 evaluable patients at that dose had confirmed tumor responses. The company announced the results Sunday at the ESMO cancer congress in Madrid and filed them with the SEC in an 8-K on Monday.

The 400 mcg/kg numbers

As of an October 1, 2026 data cut, the 11 evaluable patients at 400 mcg/kg had five confirmed partial responses (45.5%) and one unconfirmed partial response, for an unconfirmed rate of 55%. Median progression-free survival, the time before the cancer worsens, had not been reached. More than 70% of patients remained on treatment, and the 6-month progression-free survival estimate was 82%.

The cohort is small: the 95% confidence interval on the 45.5% rate runs from 16.8% to 76.6%. Xencor said safety at this dose matched the lower-dose cohorts.

XmAb819 is a bispecific antibody that targets ENPP3 on tumor cells and recruits T cells to kill them. Patients in the study had all received a PD-(L)1 inhibitor and a VEGFR-targeted pill, with a median of three prior lines of therapy.

Lower doses and safety

Of the 68 patients in the three expansion cohorts, response rates were measured in efficacy-evaluable subsets as of a September 1, 2026 data cut. The confirmed rate was 30% at 100 mcg/kg (30 patients) and 44% at 200 mcg/kg (25 patients).

Treatment was stopped over related adverse events in 5.9% of expansion patients, and 72.1% had a related event of Grade 3 or higher. The most common severe events were liver enzyme rises, rash and low blood pressure, mostly early in treatment, according to the company.

Path to a late-stage trial

Xencor plans to discuss a potential accelerated approval pathway with the FDA in the first half of 2027, for patients who have exhausted standard care. In pooled data, patients who had progressed after a PD-(L)1 inhibitor and at least two VEGFR pills (n=42) had a 45% confirmed response rate. The triple-class group that also received a HIF2α inhibitor (n=23) had 35%. Xencor's presentation estimates about 9,200 US patients fit the first group in 2025, based on Komodo Health claims data.

The company also plans a global randomized trial against tivozanib, aiming to start a registration-enabling study by the end of 2027. In a similar subgroup of another trial, tivozanib produced a 10.5% response rate and median progression-free survival of 5.4 months. Xencor cautions that cross-trial comparisons are illustrative only.

CEO Bassil Dahiyat said the company plans to start a potential registration-enabling study next year, and that cash runway into 2029 leaves it "well positioned" to push its oncology and autoimmune work.

Data from at least 20 patients at 400 mcg/kg and from subcutaneous dosing are due in the first half of 2027, alongside the end-of-Phase 1 meeting with the FDA.

Sources